<DOC>
	<DOC>NCT02711345</DOC>
	<brief_summary>A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.</brief_summary>
	<brief_title>A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patient (male or female) ≥18 years of age ECOG (Eastern Cooperative Oncology Group) performance status ≤1 Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate. Patients must be willing and able to undergo study required biopsies. Presence of at least one measurable lesion according to RECIST v1.1. Documented MAPK pathway alteration Prior treatment with ERK inhibitors. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study. Patients with malignant disease other than that being treated in the study. Clinically significant cardiac disease. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LTT462</keyword>
	<keyword>ERK</keyword>
	<keyword>MAPK</keyword>
	<keyword>solid tumor</keyword>
</DOC>